Evidence map›Paper›PMID 36361954›Full record

ArticleInternational journal of molecular sciences2022

Structure-Guided Approach to Discover Tuberosin as a Potent Activator of Pyruvate Kinase M2, Targeting Cancer Therapy.

Mohd Adnan, Anas Shamsi, Abdelbaset Mohamed Elasbali, Arif Jamal Siddiqui, Mitesh Patel, Nawaf Alshammari, Salem Hussain Alharethi, Hassan H Alhassan, Fevzi Bardakci, Md Imtaiyaz Hassan

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Mohd AdnanDepartment of Biology, College of Science, University of Ha'il, Ha'il P.O. Box 2440, Saudi Arabia.ORCID 0000-0002-7080-6822
Anas ShamsiCentre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, Jamia Nagar, New Delhi 110025, India.ORCID 0000-0001-7055-7056
Abdelbaset Mohamed ElasbaliDepartment of Clinical Laboratory Science, College of Applied Medical Sciences-Qurayyat, Jouf University, Sakaka P.O. Box 72388, Saudi Arabia.ORCID 0000-0002-7003-9846
Arif Jamal SiddiquiDepartment of Biology, College of Science, University of Ha'il, Ha'il P.O. Box 2440, Saudi Arabia.ORCID 0000-0002-6236-0920
Mitesh PatelDepartment of Biotechnology, Parul Institute of Applied Sciences and Centre of Research for Development, Parul University, Vadodara 391760, India.ORCID 0000-0002-9283-2124
Nawaf AlshammariDepartment of Biology, College of Science, University of Ha'il, Ha'il P.O. Box 2440, Saudi Arabia.
Salem Hussain AlharethiDepartment of Biological Science, College of Arts and Science, Najran University, Najran P.O. Box 11001, Saudi Arabia.ORCID 0000-0002-0352-6900
Hassan H AlhassanDepartment of Clinical Laboratory Science, College of Applied Medical Sciences-Sakaka, Jouf University, Sakaka P.O. Box 72388, Saudi Arabia.ORCID 0000-0002-7174-9831
Fevzi BardakciDepartment of Biology, College of Science, University of Ha'il, Ha'il P.O. Box 2440, Saudi Arabia.ORCID 0000-0003-3377-2763
Md Imtaiyaz HassanCentre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, Jamia Nagar, New Delhi 110025, India.ORCID 0000-0002-3663-4940
University of Ha'il · SAJamia Millia Islamia · INJouf University · SANajran University · SAParul University · IN

Funding

University of Hail MDR-22003
6 · The paper itself

Abstract

Metabolic reprogramming is a key attribute of cancer progression. An altered expression of pyruvate kinase M2 (PKM2), a phosphotyrosine-binding protein is observed in many human cancers. PKM2 plays a vital role in metabolic reprogramming, transcription and cell cycle progression and thus is deliberated as an attractive target in anticancer drug development. The expression of PKM2 is essential for aerobic glycolysis and cell proliferation, especially in cancer cells, facilitating selective targeting of PKM2 in cell metabolism for cancer therapeutics. We have screened a virtual library of phytochemicals from the IMPPAT (Indian Medicinal Plants, Phytochemistry and Therapeutics) database of Indian medicinal plants to identify potential activators of PKM2. The initial screening was carried out for the physicochemical properties of the compounds, and then structure-based molecular docking was performed to select compounds based on their binding affinity towards PKM2. Subsequently, the ADMET (absorption, distribution, metabolism, excretion and toxicity) properties, PAINS (Pan-assay interference compounds) patterns, and PASS evaluation were carried out to find more potent hits against PKM2. Here, Tuberosin was identified from the screening process bearing appreciable binding affinity toward the PKM2-binding pocket and showed a worthy set of drug-like properties. Finally, molecular dynamics simulation for 100 ns was performed, which showed decent stability of the protein-ligand complex and relatival conformational dynamics throughout the trajectory. The study suggests that modulating PKM2 with natural compounds is an attractive approach in treating human malignancy after required validation.

Indexed as

Enzyme ActivatorsIsoflavonesNeoplasmsPyruvate KinaseCell Line, TumorCell ProliferationGlucosidesGlycosidesHumansMolecular Docking SimulationPhosphate-Binding ProteinsEnzyme ActivatorsGlucosidesGlycosidesIsoflavonesPhosphate-Binding ProteinsPyruvate Kinasetuberosintuberosinine Ddrug discoverykinase activatormolecular dynamics simulationsphytoconstituentsprincipal component analysispyruvate kinase M2tuberosinvirtual screening

Identifiers

PMID36361954
PMCPMC9655700
OpenAlexW4307947514

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.